GGrantIndex
Sort

48,018 grants matching immunotherapy

Lineage heterogeneity and plasticity in lung cancer

$498,257
Hideo Watanabe · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA

Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens

$498,243
Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Cyclin Dependent Kinases as Epigenetic Therapy Targets

$498,235
Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2023 · CA

Cyclin Dependent Kinases as Epigenetic Therapy Targets

$498,233
Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2022 · CA

Tissue engineering tools for monitoring the cellular and molecular response to therapy

$498,230
Lonnie D Shea · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

Multiscale data geometric networks for learning representations and dynamics of biological systems

$498,229
Smita Krishnaswamy · Yale University · · FY2023 · MPS

INSIDE-OUT IMMUNOTHERAPY: PREVENTING METASTATIC BREAST CANCER RECURRENCE VIA NANOPARTICLE-DIRECTED MODULATION OF THE TUMOR MICROENVIRONMENT

$498,227
Vanderbilt University, The · · FY2016 · Department of the Army

Transfusion Biology and Medicine

$498,113
Leslie Eric Silberstein · Boston Children'S Hospital · T32 · FY2009 · HL

Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for Presentio

$498,100
Claudio Anasetti · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2014 · HL

Overcoming stromal barriers to therapeutics in pancreas cancer

$497,999
Sunil R Hingorani · Fred Hutchinson Cancer Research Center · R01 · FY2019 · CA

UCLA Tumor Immunology Institutional Traning Grant

$497,990
Michael A Teitell · University Of California Los Angeles · T32 · FY2018 · CA

Resource for Nonhuman Primate Immune Reagents

$497,967
Francois J Villinger · Emory University · R24 · FY2012 · OD

Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary Carcinomas

$497,964
Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2023 · CA

Optimized ultrasound-enhanced immunotherapy

$497,935
Katherine W Ferrara · University Of California At Davis · R01 · FY2017 · CA

DKK2 regulates NK activation and tumor immunity

$497,913
Dianqing Wu · Yale University · R01 · FY2019 · CA

Regulators of Cancer Immunotherapy Response

$497,881
Xiaole Shirley Liu · Dana-Farber Cancer Inst · R01 · FY2019 · CA

Multiscale Computational Models Guided By Emerging Cellular Dynamics Quantification For Predicting Optimum Immune Checkpoint And Targeted Therapy Schedules

$497,777
Trachette Jackson · University Of Michigan At Ann Arbor · U01 · FY2020 · CA

Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer

$497,774
Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA

Metabolic Impacts of Type II Interferon Signals in Obesity

$497,758
Sean Hartig · Baylor College Of Medicine · R01 · FY2025 · DK

Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary Carcinomas

$497,714
Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2021 · CA

Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis

$497,648
Weizhou Zhang · University Of Florida · R01 · FY2023 · CA

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma

$497,607
Darell D Bigner · Duke University · P01 · FY2021 · CA

Role of Neutralizing Antibodies in Transmission of SHIV

$497,587
Nancy Logan Haigwood · Oregon Health & Science University · R01 · FY2009 · HD

Mechanisms of uveal melanoma dormancy and targeted therapy tolerance

$497,523
Andrew E Aplin · Thomas Jefferson University · R01 · FY2020 · CA

Molecular mechanisms and therapeutic targeting of PI3K-p110beta/PTEN signaling in breast cancer and cancer immunity

$497,522
Thomas M Roberts · Dana-Farber Cancer Inst · R01 · FY2019 · CA